The effect of *Cornus mas* in preventing recurrent urinary tract infections in women: A randomized controlled trial

Narjeskhaton Dadkhah¹, Majid Shirani²*, Shahram Etemadifar¹, Mahdiesadat Mirtalebi³

¹Nursing and midwifery Dept., Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran; ²Urology Dept., Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran; ³General Practitioner, Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran.

ABSTRACT

Background and aims: Urinary tract infections (UTIs) are one of the most common and the second leading infections, after respiratory tract infections, in women. Currently, various chemical drugs are used to prevent the UTIs. Chemical drugs may cause antibiotic resistance and cause resistant strains likely grow in the long-term treatment with antibiotics. The aim of this study was to investigate the effect of *Cornus mas* in preventing recurrent UTIs in women aged 15-45 years referring to Ayatollah Kashani Hospital Clinic in Shahrekord.

Methods: This experimental study (Parallel Design and Triple-blind) was conducted on 42 women aged 15-45 years referring to Ayatollah Kashani Hospital Clinic of Shahrekord and diagnosed with chronic cystitis. The exclusion criteria were neurogenic bladder, genitourinary system anatomical abnormalities (hydronephrosis, ureterocele stone, etc), and bacterial resistance. The women were randomly assigned to 2 groups. At baseline, the women were examined for any functional and anatomical disorders and if it was necessary, they underwent ultrasound. After the current UTIs were treated and the women clinically recovered, one group was administered with *Cornus mas* tablet 500 mg and another group administered with placebo for 6 months. All the women were followed up for 6 months. Every 2 months, the patients were clinically examined and their urine cultures were investigated for the clinical signs of cystitis. As the symptoms of the UTIs occur, the patients were recommended to refer for repeated urine culture. All patients (42 women) completed the study.

Results: In our study, no significant difference was observed between the groups in terms of recurrent UTI recurrence, although there were differences (P>0.005). Positive urine culture in *Cornus mas* group was 19% and in placebo was 33.4%. In terms of dysuria in 6 months and the second time, there was a significant difference between placebo and *Cornus mas* (P=0.004) Dysuria in *Cornus mas* group was 14.2% and in placebo was 56.2%.

Conclusion: *Cornus mas* can decrease dysuria and frequent urination in patients with recurrent UTIs, so it can be used in the treatment of these patients.

Keywords: *Cornus mas*, Urinary tract infections, Treatment.

INTRODUCTION

Each year, over 250 million people worldwide develop urinary tract infection (UTI).¹ The UTIs are the second leading infection, after respiratory diseases, in
women, older people, and infants. These infections are caused due to urinary tract microorganisms, and can be symptomatic or asymptomatic. *Escherichia coli*, followed by *Proteosolgaris*, is the leading bacterial cause of the UTIs. *Klebsiella pneumoniae*, *Staphylococcus epidermidis*, Enterobacter, Citrobacter, and *Pseudomonas aeruginosa* can be other bacterial causes of the UTIs. In symptomatic UTIs, certain symptoms may be seen, including frequent urination, dysuria, urinary incontinence, forcing urine out, strong-smelling urine, and in some cases, fever. According to the available evidence, the incidence of ampicillin and amoxicillin resistance is 100% in the gram-negative bacilli from Enterobacteriaceae. Moreover, the resistance of different Staphylococcal strains has been reported to be 70%-90%. The side effects due to antibiotics and increasing antibiotic resistance have led to increased attention to herbal drugs and nature-based antimicrobial agents.

*Coron Mas* (*C. mas*) is from family Valerian and rich in anthocyanins, which can be the cause of its pharmacological properties, including antioxidant, anti-allergy, antibacterial, and anti-inflammatory.

Uropathogenic adhesion to urinary tract cells is the first step of the UTI pathogenesis. The anti-adhesion property of *C. mas* can contribute to the prevention of the UTIs either directly through *Escherichia coli* adhesion to uroepithelial cells or through decreased bacterial adhesion in stool. Recent studies have demonstrated that regular use of *C. mas* is helpful for the patients with UTIs who have antibiotic resistance.

*C. mas* juice has become popular as a natural alternative for the prevention of urinary tract infections (UTIs), which have a high incidence in women and elderly persons. Moreover, *C. mas* juice has shown efficacy in reducing UTIs in women with recurrent episodes and in reducing bacteriuria in elderly persons. Clinical benefits are associated with chronic use (months) and with a regular frequency of consumption (daily). Studies have shown that the prophylactic nature of *C. mas* juice is a result of inhibition of the adhesion of bacterial fimbriae to uroepithelial cells, rather than because of urinary acidification. *C. mas* juice also has shown a beneficial effect against drug-resistant bacteria. The anti-adhesion property of *C. mas* has been reported to persist for 2-10 hours after use. Anticianidine, a compound found in *C. mas*, can prevent the pathogens adhesion to uroepithelial cells. Some studies have reported that *C. mas* can decrease the incidence of recurrent UTIs and some others have found no (predictable) effects of *C. mas* in the incidence of the recurrent UTIs.

Moreover, inconsistent findings have been obtained on *C. mas* effects on the UTIs. Regarding the high prevalence of the UTIs in the community and because the people of Chaharmahal and Bakhtiari province have long been using plants to treat diseases, especially the UTIs, we conducted this study to investigate the effects of *C. mas* on the recurrent UTIs in women aged 15-45 years. Study of Chypsvn and colleagues on the effects of prophylactic *C. mas* showed in urinary tract infections *C. mas* juice was effective in reducing urinary tract infection but has no effect on other variables, because gastrointestinal side effects for patients after consumption of *C. mas* juice, that was left
taking it, So, it was used in this study *C. mas* tablet form.\textsuperscript{13}

**METHODS**

This randomized clinical trial was done on 2 groups (each group: 21) of 15-45 years old women with different weight and recurrent cystitis who referred to Clinic of Shahrekord Kashani hospital in 2013 that sample size was determined using the software Stata and according to the available studies. The subjects were matched in view of the year's old, length of disease, level of education, social category, place of life and quality of individual health. Then, using SPSS the subjects were allocated to groups randomly, Patients, sampling and analyzer of data were blinded. This study was approved by ethical committee of Shahrekord University of Medical Sciences and was done with ethical code (4-3-93) and code of Iranian randomized clinical trial center (IRCT2015111625072N1). Written informed consent was obtained from all subjects and other ethical principals were achieved. Before the subjects were enrolled in the study, their anatomical and functional problems were examined and sonography and intravenous pyelography were done if it was necessary. The subjects with anatomical problems of urinary system (kidney stone, urethrocel, hydronephrosis) and dysfunction of urinary system (neurogenic bladder) were excluded from study. Because of differences in the number of subjects' intercorsing and prevention of study error, it was applied a long time and low dose of consuming the drug in this study. After treatment of primary urinary infection and promoting clinical status, we gave the *C. mas* tablet (500 mg, Based on existing studies) to the first group for 6 month nightly and the placebo to the second group for 6 months nightly. For extraction, 30 kg of *C. mas* prepared by the city of Qazvin, Iran was dried in shadow gradually and converted to powder by mechanical milling, and then the powder was mixed with ethanol 70% (1 vs. 5) by maceration method for 4 days. The extraction was passed from filter paper and was concentrated under vacuum by rotary operator machine. Then, concentrate extract was knead with calcium triphosphate and dried in granulation form. After the standardization by assessing the anthocyanin content, we filled the tablets with *C. mas* granule. For making the placebo, it was provided dough from starch and starch paste and converted to dried granule, and then the same tablets were filled by the dried herb extract.\textsuperscript{14} The patients were followed for 6 months and stayed on clinical examination, urine analyzing, urine culturing and assessing for cystitis clinical sign (dysuria, incontinency and suprapubic pain). The patients with positive test were excluded from the study and treated for their recurrent infection and recommended them for repeating urine culture whenever if infection sign was seen. During the months 2,4,6, after urine culturing, urine incontinence, dysuria, abdominal pain were assessed and signed in the checklist by the researcher. The data were calculated and analyzed with chi-square test using SPSS software.

**RESULTS**

In the *C. mas*-treated group, 4(19\%) people developed recurrent UTI and in the placebo group, 7(33.4\%) did. Although there were some
Differences in the mean incidence of the recurrent UTIs during the 6 months, chi-square test indicated no significant difference in the incidence of the recurrent UTIs between the 2 groups (P>0.005). Chi-square test indicated no significant difference in the urine culture in the first, the second, and the third two-month periods between the 2 groups (P>0.005) (Table 1, Figure 1).

It should be noted, All participants continued to the end of the intervention (n= 21 per group).

**Table 1:** The frequency distribution of the urine culture in the groups of the study

<table>
<thead>
<tr>
<th>Groups</th>
<th>Placebo</th>
<th>Cornus mas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variables</td>
<td>Positive urine</td>
<td>Negative urine</td>
</tr>
<tr>
<td></td>
<td>culture</td>
<td>culture</td>
</tr>
<tr>
<td>During 6 months</td>
<td>7(33.4%)</td>
<td>14(66.6%)</td>
</tr>
<tr>
<td>The first 2 months</td>
<td>5(23.2%)</td>
<td>16(76.2%)</td>
</tr>
<tr>
<td>The second 2 months</td>
<td>1(4.8%)</td>
<td>20(95.2%)</td>
</tr>
<tr>
<td>The third 2 months</td>
<td>1(4.8%)</td>
<td>20(95.2%)</td>
</tr>
</tbody>
</table>

*P<0.005 was considered the level of significance.*

Moreover, there were some differences in the frequent urination between the 2 groups, but chi-square test indicated no significant difference in the frequent urination during the 6 months between the 2 groups (P>0.005). During the 6 months, in the placebo group, 38% developed frequent urination and in the *C. mas*-treated group, 22.4% did. In other words, the frequent urination decreased in the *C. mas*-treated group by 15.6% compared to the placebo group (Table 2, Figure 2).
Table 2: The frequency distribution of the frequent urination in the groups of the study

<table>
<thead>
<tr>
<th>Groups</th>
<th>Placebo</th>
<th></th>
<th>Cornus mas</th>
<th></th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative frequent urination</td>
<td>Positive frequent urination</td>
<td>Negative frequent urination</td>
<td>Positive frequent urination</td>
<td></td>
</tr>
<tr>
<td>During 6 months</td>
<td>16 (76.2%)</td>
<td>5 (22.4%)</td>
<td>13 (62%)</td>
<td>8 (38%)</td>
<td>351.0</td>
</tr>
<tr>
<td>The first 2 months</td>
<td>19 (90.4%)</td>
<td>2 (9.6%)</td>
<td>18 (85.8%)</td>
<td>3 (14.2%)</td>
<td>0.852</td>
</tr>
<tr>
<td>The second 2 months</td>
<td>19 (90.4%)</td>
<td>2 (9.6%)</td>
<td>18 (85.8%)</td>
<td>3 (14.2%)</td>
<td>0.852</td>
</tr>
<tr>
<td>The third 2 months</td>
<td>19 (90.4%)</td>
<td>2 (9.6%)</td>
<td>17 (81%)</td>
<td>4 (19%)</td>
<td>0.325</td>
</tr>
</tbody>
</table>

*P* < 0.005 was considered the level of significance.

**Figure 2:** The frequency distribution of the frequent urination in the groups of the study in 6 months.

In addition, there were some differences in abdominal pain between the 2 groups of the study, but chi-square test indicated no significant difference in abdominal pain between the 2 groups during the 6-month period (*P* > 0.005). During the 6 months, in the placebo group, 19% of the women developed abdominal pain and in the *C. mas*-treated group, 4.8% did.

There were some differences in dysuria between the first and the second 2 months, but chi-square test indicated no significant difference in dysuria between the first and the second 2 months (*P* > 0.005). Chi-square test indicated a significant difference in dysuria in the second 2 months (the fourth month) and during the 6-month months between the placebo group and the *C. mas*-treated group (*P* < 0.005). Within the 6 months, in the placebo group, 57.2% of the women developed dysuria and in the *C. mas*-treated group, 14.2% did. More clearly, dysuria decreased in the *C. mas*-treated group by 43% compared to the placebo group (Table 3, Figure 3).
Table 3: The frequency distribution of dysuria in the groups of the study

<table>
<thead>
<tr>
<th>Groups</th>
<th>Placebo</th>
<th></th>
<th>Cornus mas</th>
<th></th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative dysuria</td>
<td>Positive dysuria</td>
<td>Negative dysuria</td>
<td>Positive dysuria</td>
<td></td>
</tr>
<tr>
<td>During 6 months</td>
<td>18(85.8%)</td>
<td>3(14.2%)</td>
<td>9(42.8%)</td>
<td>12(57.2%)</td>
<td>0.004</td>
</tr>
<tr>
<td>The first 2 months</td>
<td>19(90.4%)</td>
<td>2(9.6%)</td>
<td>15(71.4%)</td>
<td>6(28.6%)</td>
<td>0.116</td>
</tr>
<tr>
<td>The second 2 months</td>
<td>20(95.2%)</td>
<td>1(4.8%)</td>
<td>15(71.4%)</td>
<td>6(28.6%)</td>
<td>0.038</td>
</tr>
<tr>
<td>The third 2 months</td>
<td>20(95.2%)</td>
<td>1(4.8%)</td>
<td>16(76.2%)</td>
<td>5(22.4%)</td>
<td>0.078</td>
</tr>
</tbody>
</table>

P<0.005 was considered the level of significance.

Figure 3: The frequency distribution of dysuria in the groups of the study in 6 months

DISCUSSION

This study was conducted to compare the effects of C. mas tablet and placebo in preventing the recurrent UTIs in the women aged 15-45 years referring to Ayatollah Kashani Hospital Clinic of Shahrekord. The UTIs are one of the most common reasons for referring of the outpatients to health care centers. These infections may lead to hospital stay due to critical conditions or an underlying debilitating disease in the patient. In the present study on 42 women with recurrent UTIs during 6 months, there were some differences in the recurrent UTIs between the 2 groups yet statistically non-significant. The urinary tract symptoms also were studied, and there was a statistically significant difference in dysuria between the placebo and the C. mas-treated groups. In Kontiokari et al study on 150 women with recurrent UTIs, the incidence of the UTIs decreased after 6 months of using concentrated C. mas. In this study, the overall incidence of the recurrent UTIs during 12 months was statistically significantly different between the case and the control groups (P=0.048). In the case group, treated with C. mas extract for 6 months, 16% of the patients developed recurrent UTI at least once, while in the control group, 36% did. The incidence of the recurrent UTIs decreased in the case group by 20% compared to the control group, which is inconsistent with our study. This may be due to conducting a study during a longer period of time compared to our study. Moreover, Takahashi et al investigated the effects of C. mas juice in preventing the recurrent UTIs in a small number of women who used
C. mas juice for 24 weeks, and found the C. mas juice to be effective in preventing these infections. However, in the present study, the tablets of C. mas were used and no significant difference was seen in the incidence of the recurrent UTIs between the 2 groups. This inconsistency may be due to the differences in the concentrations of effective compounds between the C. mas tablet and pure juice.

Hess et al investigated the effects of C. mas tablet in preventing the UTIs in spinal cord lesion (SCL) patients with neurogenic bladder. The patients were randomly assigned to two groups, the controls and the C. mas tablet, respectively, for 6 months. After 6 months, the clinical symptoms of the UTIs decreased probably due to taking the C. mas tablets and even, compared to the controls, the frequency of the UTIs incidence per year decreased. Similarly, in our study, the C. mas tablet was used and the urinary tract symptoms decreased, partly in the case group compared to the controls, but the recurrent UTIs did not decrease significantly. Barbosa-Cesnik et al investigated the effects of C. mas juice on the risk of the recurrent UTIs incidence in 319 female university students. In this study, the incidence of the recurrent UTIs did not decrease in the group who used C. mas juice twice a day compared to the placebo-receiving group during a period of 6 months. In our study, C. mas tablet was used, and consistent with Barbosa-Cesnik et al study, no significant decrease was seen in the recurrent UTIs between the 2 groups of the study. In a study on 48 SCL patients with neurogenic bladder, 22 patients received placebo and 26 were administered with the C. mas tablet. The C. mas tablet was found to cause bacteriuria and pyuria in the SCL patients.

In another study on SCL patients with neurogenic bladder, C. mas tablet had no effect in reducing bacterial colony counts, pyuria, and the incidence of the UTIs in these patients. Similarly, the present study demonstrated that use of C. mas tablet caused no decrease in the recurrent UTIs. In the current study, the incidence of recurrent UTIs was 19% and 33.4% in the C. mas-treated and the placebo groups, respectively, with no significant difference. Uropathogenic adhesion to urinary tract cells is considered the first step of the UTIs pathogenesis. The anti-adhesion property of C. mas can prevent the UTIs through 2 mechanisms, directly through E. coli adhesion to urothelial cells or through helping to decrease bacterial adhesion in stool. Because the anti-adhesion property of C. mas can persist for 2-10 hours after use, the incidence of the recurrent UTIs is more likely to decrease if each day 2 C. mas tablets are used. Regarding other studied variables, such as frequent urination and abdominal pain, some differences were seen but they were not statistically significant within the 6 months according to chi-square test.

CONCLUSION

Regarding the findings of this study on C. mas and botanical evidence on use of this plant to treat the UTIs, use of C. mas tablet 500 mg a day can decrease dysuria among patients with UTIs. The findings of this study can be an introduction to reducing the incidence of the recurrent UTIs and dysuria in patients with UTIs. Patients, especially those with allergy to chemical drugs, can be recommended to use C. mas tablet as it is plant-based.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interests.

ACKNOWLEDGEMENT

The authors gratefully thank the Research and Technology Deputy of the Shahrekord
University of Medical Sciences for funding this work. This study have IRCT2015111625072N1 Code clinical trials.

REFERENCES